Day One Biopharmaceuticals, Inc. DAWN 深 滬
已收盤 02-06 16:00:00 美东时间
11.41
+0.930
+8.87%
華盛通- 最 高11.50
- 今 開11.06
- 成交量 312.98万股
- 最 低 10.8414
- 昨 收 10.48
- 總市值 11.72亿
- 52周最高 13.20
- 市盈率 靜 --
- 換手率 3.05%
- 52周最低 5.635
- 委 比 47.31%
- 總股本 1.03亿
- 歷史最高 28.699
- 量 比 1.61
- 振 幅 6.28%
- 歷史最低 5.44
- 每 手 1
- 風險率 1.69%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股牛股 | Corvus制药飙升166%，皮炎新药1期临床试验结果积极；RAPT大涨逾60%
Corvus制药飙升166%，皮炎新药临床试验结果积极；RAPT大涨逾60%，获葛兰素史克以22亿美元溢价收购；黄金资源大涨24%，财报强劲叠加金银价齐创新高>>
01-21 18:51
Day One Biopharmaceutical shares are trading higher after TD Cowen initiated coverage on the stock with a Buy rating and announced a $34 price target.
Day One Biopharmaceutical shares are trading higher after TD Cowen initiated co...
01-21 02:35
美股大行评级 | 高盛上调谷歌目标价从330美元升至375美元；5家大行集体上调Five Below目标价最高至255美元
今日重点评级关注：HC Wainwright & Co.：维持NioCorp Developments"买入"评级，目标价从9.5美元升至11.25美元；摩根士丹利：维持Chewy"超配"评级，目标价从48美元升至51美元
01-14 11:25
美股牛股 | 私人航空公司UP单日暴涨46%！One Stop大涨29%，获美军预生产订单
私人航空公司UP单日暴涨46%！One Stop股价涨29%，获美军预生产订单；BIOA涨逾27%，核心在研药获突破进展>>
01-13 17:24
Planet Labs PBC, Day One Biopharmaceuticals, Rxsight, SunOpta And Other Big Stocks Moving Higher On Monday
U.S. stocks were lower, with the Dow Jones index falling around 200 points on M...
01-12 23:07
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers MoonLake (NASDAQ:MLTX) stock rose 8.2% to $20.0 during Friday's after-...
01-10 05:05
FuelCell Energy Posts Strong Q4 Results, Joins Trump Media & Technology, Micron Technology, Lululemon And Other Big Stocks Moving Higher On Thursday
U.S. stocks were higher, with the Dow Jones index gaining more than 300 points ...
2025-12-18 23:10
美股大行评级 | 摩根大通上调百度至"超配"，目标价升至188美元！Navan获多家机构首予"买入"评级，目标价最高30美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从4美元升至9美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从32美元升至38美元
2025-11-25 10:27
Day One Biopharma Announces 3-Yr Results From OJEMDA Pivotal Phase 2 FIREFLY-1 Trial In Oral Presentation At 2025 SNO Annual Meeting
Updated data expands clinically meaningful results available from FIREFLY-1 pivotal trial 77% of patients who entered the treatment-free observation period following OJEMDA treatment remained off therapy for at
2025-11-24 21:03
Day One Biopharmaceuticals Agrees To Acquire Mersana Therapeutics For $25 Per Share In Cash Plus One Non-tradable CVR Up To An Aggregate Of $30.25 Per CVR In Cash
Under the terms of the definitive merger agreement, Day One will promptly commence a tender offer to acquire all of the outstanding shares of Mersana common stock at a price of $25 per share in cash at closing plus one
2025-11-13 19:05
